Prosensa [SEP] inception
Prosensa
Prosensa was a biotechnology company engaged in the discovery, development and commercialization of RNA-modulating therapeutics. The company targets genetic disorders with a large unmet medical need, with a primary focus on neuromuscular and neurodegenerative disorders such as Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy and Huntington's disease. Prosensa was acquired by BioMarin 
History up to the sale.
Prosensa commenced operations in 2002 and is located in Leiden, The Netherlands. The company works closely together with academia, patient groups and experts worldwide. Prosensa
III trials were sponsored by GlaxoSmithKline but GSK terminated the collaboration agreement between GSK and Prosensa and Prosensa has regained all rights from GSK to drisapersen. Prosensa was then acquired by BioMarin Pharmaceutical, which continued the development of drisapersen and was concurrently working with similar exon skipping therapies for other exons.
Both drisapersen and the similar drug eteplirsen have filed a New Drug Application (NDA) for review with the US Food and Drug Administration (FDA). In January 2016, the FDA rejected drisapersen (Kyndrisa) after it concluded that the